Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?

Cholesterol metabolism and transport has been a major focus in cardiovascular disease risk modification over the past several decades. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) have been the most commonly used agents, with the greatest benefit in reducing both the primary and secondary risks of cardiovascular disease. However, heart disease remains the leading cause of death in both men and women in the United States. Further investigation and intervention are required to further reduce the risk for cardiovascular disease and cardiovascular-related deaths. This review will focus on high-density lipoprotein metabolism and transport, looking particularly at cholesteryl ester transfer protein (CETP) inhibitors. While studies of the other CETP inhibitors in its class have not shown a significant improvement in the prevention of primary or secondary cardiovascular risk, anacetrapib, the fourth and latest of the CETP inhibitors to be investigated, may be more promising.
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research

Related Links:

A deep-learning algorithm refines cardiac CT results by automatically eliminating...Read more on AuntMinnie.comRelated Reading: CT CAC directs statin therapy in African Americans CT CAC predicts risk of death in smokers AI spots heart disease on CT lung screening exams CT CAC linked to cardiovascular mortality in young adults Elevated CT CAC scores linked to future heart failure
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
(CNN) — Still taking a daily aspirin to ward off heart attacks? You might want to think again, according to a new review. Aspirin is still one of the most commonly used medications in the world, even though it’s no longer recommended as a preventative by many health authorities. There is no evidence that low-dose aspirin — less than 325 milligrams a day — should be taken by most adults in good cardiovascular health, according to a new review of existing research that published Wednesday in the British Journal of Clinical Pharmacology. The review, which focused on the risks and benefits of low-dose d...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News aspirin CNN Source Type: news
Abstract Atherosclerosis (AS) is the main pathological cause of coronary heart disease (CHD). Current clinical interventions including statin drugs can effectively reduce acute myocardial infarction and stroke to some extent, but residual risk remains high. The current clinical treatment regimens are relatively effective for early atherosclerotic plaques and can even reverse their progression. However, the effectiveness of these treatments for advanced AS is not ideal, and advanced atherosclerotic plaques-the pathological basis of residual risk-can still cause a recurrence of acute cardiovascular and cerebrovascul...
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharmacol Sin Source Type: research
There are clear gender differences in the medication prescribed in primary care to adults with or at high risk for heart disease, with women less apt than men to receive aspirin and statins, a new study indicates.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
This study explores the cost-effectiveness of this strategy from the perspective of the Australian public healthcare system.
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research
This study aimed to investigate the effects of a China Food and Drug Administration (CFDA)-approved prescription medicine, Tongxin, on the density and function of endothelial progenitor cells (EPCs) in peripheral blood. Design: In this study, a randomized, single blind, parallel controlled clinical trial was used. The single blind subjects were subjects. Setting: The study took place in the Cardiology and Emergency Departments at Shanghai Municipal Hospital of Traditional Chinese Medicine in Shanghai, China. Participants: Participants were 48 patients with coronary heart disease at the hospital. Interve...
Source: Alternative Therapies in Health and Medicine - Category: Complementary Medicine Authors: Tags: Altern Ther Health Med Source Type: research
Abstract Simvastatin a cholesterol-lowering agent used to treat hypercholesterolemia, coronary heart disease, and dyslipidemia. However, simvastatin (SV) has shown low oral bioavailability in GIT. The main purpose of the work was to develop proliposomal formulations to increase the oral bioavailability of SV. Film deposition on the carrier method has been used to prepare the proliposomes. The proliposomes were assessed for morphology, particulate size, entrapment efficacy, drug-polymer compatibility, in vitro and in vivo studies. FTIR and DSC results revealed no drug-polymer interaction. SEM and XRD analysis confo...
Source: AAPS PharmSciTech - Category: Drugs & Pharmacology Authors: Tags: AAPS PharmSciTech Source Type: research
The COVID crisis has decimated water exercise. Can we rethink pool closures? A significant number of my older patients relied on pools for their fitness. During a pandemic, you can stay active or fit only if you have good legs and joints. Walkers, runners, and cyclists have no problem; they play outside in the Spring weather. People with bone/joint problems, fitness swimmers, and young children who normally take swim lessons this time of year are out of luck. Consider the place I swim—the Mary T Meagher Natatorium, named after Mary T, a Louisville native, who won Olympic gold in 1984. The place is an ode to Sp...
Source: Dr John M - Category: Cardiology Authors: Source Type: blogs
ConclusionsPatients who visited their GP at least three times per year had a lower risk of ceasing their statins in the year following the copayment increase. GPs can help patients maintain treatment following rises in medicines costs.What is known about the topic?Following the 21% increase in medication copayment in 2005, individuals discontinued or reduced their statin usage, including for tertiary prevention.What does this paper add?Patients who visited their GP at least three times per year were less likely to discontinue their statin therapy for tertiary prevention following a large copayment increase.What are the imp...
Source: Australian Health Review - Category: Hospital Management Authors: Tags: Aust Health Rev Source Type: research
(Natural News) Nearly every medication has side effects, but sometimes people are willing to take them on to get some sort of benefit. And while no one wants to deal with heart disease and its effects on the body, taking popular cholesterol medications could bring on another potentially deadly illness: type 2 diabetes. This is...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Heart Disease | Statin Therapy | Study | USA Health | Women